Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group.
about
Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal womenNSABP breast cancer clinical trials: recent results and future directionsAdvances in estrogen receptor biology: prospects for improvements in targeted breast cancer therapyOptimal management of hormone receptor positive metastatic breast cancer in 2016Development of new estrogen receptor-targeting therapeutic agents for tamoxifen-resistant breast cancerReview of hormone-based treatments in postmenopausal patients with advanced breast cancer focusing on aromatase inhibitors and fulvestrantPharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the 'Arimidex and tamoxifen alone or in combination' (ATAC) trialAromatase inhibitors and inactivators in breast cancerUse of the aromatase inhibitor anastrozole in the treatment of patients with advanced prostate carcinoma.Cost-effectiveness analysis of exemestane compared with megestrol in patients with advanced breast carcinoma.Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer.Variation in anastrozole metabolism and pharmacodynamics in women with early breast cancer.Altering the estrogenic milieu of breast cancer with a focus on the new aromatase inhibitors.Current and future directions in medical therapy for breast carcinoma: endocrine treatment.Pharmacology and clinical experience with exemestane.Aromatase inhibitor strategies in metastatic breast cancer.New drugs in breast cancer.Anastrozole (Arimidex)--an aromatase inhibitor for the adjuvant setting?Exemestane: a potent irreversible aromatase inactivator and a promising advance in breast cancer treatment.The war on cancer: a report from the front linesAromatase inhibitors for treatment of postmenopausal patients with breast cancer.Estrogens and their precursors in postmenopausal women with early breast cancer receiving anastrozole.New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane.Safety issues surrounding the use of aromatase inhibitors in breast cancer.Pharmacoeconomic considerations in the treatment of breast cancer.Targeted T-cell Therapy in Stage IV Breast Cancer: A Phase I Clinical Trial.Exemestane and aromatase inhibitors in the management of advanced breast cancer.Clinical utility of exemestane in the treatment of breast cancerAromatase inhibition in the treatment of advanced breast cancer: is there a relationship between potency and clinical efficacy?Phase II Trial of Goserelin and Exemestane Combination Therapy in Premenopausal Women With Locally Advanced or Metastatic Breast Cancer.The pitfall of the transient, inconsistent anticancer capacity of antiestrogens and the mechanism of apparent antiestrogen resistanceChanges in endocrine therapy: anastrozole and advanced breast cancer in postmenopausal women.Preclinical and clinical experience with fulvestrant (Faslodex) in postmenopausal women with hormone receptor-positive advanced breast cancer.Bone loss and the aromatase inhibitorsPatterns in target-directed breast cancer research.The adjuvant endocrine treatment revolution: focus on anastrozole.Second- and third-generation aromatase inhibitors as first-line endocrine therapy in postmenopausal metastatic breast cancer patients: a pooled analysis of the randomised trials.Phase II study of sequential hormonal therapy with anastrozole/exemestane in advanced and metastatic breast cancer.Effect of neoadjuvant treatment with anastrozole on tumour histology in postmenopausal women with large operable breast cancerAnastrozole ('Arimidex') blocks oestrogen synthesis both peripherally and within the breast in postmenopausal women with large operable breast cancer.
P2860
Q24246391-4CE1B1F5-A75D-4B9F-85BF-6A0F02971C84Q24520573-9321A4D0-5A94-40C1-BEFF-FB7FC23DBBF5Q24803990-AE51A6B7-704C-4394-837A-3654F681ACF3Q26777683-570D8E10-B5B0-4052-A8A9-3F9E043C8500Q26825584-E4F1DAAC-65AA-414A-957F-AF2E5E531F8BQ28076777-6126EE71-19B9-4D43-8E9F-E2C1C10AE829Q28345359-6DE6D83F-E362-44D6-AE7A-102E693B1BC1Q28362331-8A9066BE-9F84-41C4-BD86-58B8FD24C18CQ30308047-5123E74A-2AE3-4CE7-91E4-E12E1478DFE4Q31911601-86048C22-6DBC-4AD8-B2C4-01D3B69CE3FEQ33197385-AA6195A3-F719-4AC8-A653-A451E72DE649Q33793932-3FD4A71E-B5B0-4F5A-9E7C-9441DF1A29D9Q33871478-762DF402-6EEA-480A-9172-39CCE8FC4B99Q33970582-D9390556-5E7D-431A-B46A-3B290437092FQ34075034-8CE6E82E-D1D2-4676-962B-68D1A15EBC80Q34272016-D6C87C42-C2D1-40B4-936C-63F49909506DQ34390307-025A7B1F-CC11-4C12-9C99-E8ACDD8A0939Q34568119-C64A9263-A413-41CE-831E-71C14434ACC1Q34734021-4685F134-5184-41C7-B87B-2EAFF4B7B248Q35103643-B32F682E-1F9D-4E75-A7CB-7068E87F3551Q35117738-197C88B7-6B71-461C-947D-9AC67C796C60Q35118969-FDB23588-813D-4500-BE34-7BFEB56B3C37Q35168124-50791E4D-D1DB-4C5C-A89D-72639618ACC8Q35194446-3E57285D-29F5-4743-ADA2-08FD5314B851Q35205385-69B09116-E79F-45B3-B1F8-66E43FC8E99BQ35612933-6DF072CF-2949-434F-A09A-4D5B7FBF5CCAQ35680589-63DFC872-7B14-417C-9511-082A4E6EC84CQ35683807-1E1E4B4C-3E90-4ECA-A647-00360EFC829BQ35776951-C2CE7D2F-5763-4A85-808F-3DD7D31387BBQ35857809-34F562AB-665A-43F2-99D9-81D3E050452BQ35939435-43B34666-6273-4529-AEF1-9775A712382CQ35990530-CF398B86-B1AC-493C-B5BD-A67497DEC18CQ36090532-8ADBC695-CBF0-4870-9901-DEE696C2B6F8Q36229440-49F27CD9-2B49-4BF4-8829-962DA225081CQ36526547-378AEB84-43FF-49A8-8AE5-B4C0A10E200AQ36546281-87649CDE-03F6-4963-A788-1779033732B4Q36614435-71DA3B9E-42F4-47D2-A0D0-04FF878B8C7FQ36616775-2EFB5F6C-AE14-4CF4-ADD8-49038799BA58Q36624026-C5D1ED82-EFCF-408E-8DE6-0B2EA482EFACQ36624354-657B25FA-7145-42EE-8562-DC260CABBAA5
P2860
Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group.
description
1998 nî lūn-bûn
@nan
1998 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
name
Anastrozole versus megestrol a ...... trials. Arimidex Study Group.
@ast
Anastrozole versus megestrol a ...... trials. Arimidex Study Group.
@en
type
label
Anastrozole versus megestrol a ...... trials. Arimidex Study Group.
@ast
Anastrozole versus megestrol a ...... trials. Arimidex Study Group.
@en
prefLabel
Anastrozole versus megestrol a ...... trials. Arimidex Study Group.
@ast
Anastrozole versus megestrol a ...... trials. Arimidex Study Group.
@en
P2093
P1433
P1476
Anastrozole versus megestrol a ...... trials. Arimidex Study Group.
@en
P2093
Blomqvist CP
Eiermann W
Steinberg M
P304
P356
10.1002/(SICI)1097-0142(19980915)83:6<1142::AID-CNCR13>3.3.CO;2-7
P407
P577
1998-09-01T00:00:00Z